Search hospitals > District of Columbia > Washington

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Claim this profile
Washington, District of Columbia 20007
Global Leader in Breast Cancer
Global Leader in Lymphoma
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Leukemia
377 reported clinical trials
20 medical researchers
Photo of Lombardi Comprehensive Cancer Center at Georgetown University Medical Center in WashingtonPhoto of Lombardi Comprehensive Cancer Center at Georgetown University Medical Center in WashingtonPhoto of Lombardi Comprehensive Cancer Center at Georgetown University Medical Center in Washington

Summary

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Lymphoma, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Leukemia and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 316 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Stephen V. Liu, Claudine Isaacs, MD, and Chul Kim.

Area of expertise

1Breast Cancer
Global Leader
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center has run 55 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Lymphoma
Global Leader
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center has run 54 trials for Lymphoma. Some of their research focus areas include:
Stage III
Stage IV
MYC positive

Top PIs

Clinical Trials running at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Non-Small Cell Lung Cancer
Lung Cancer
Skin Cancer
Stomach Cancer
KRAS Mutation
Uterine Tumors
Solid Tumors
Cancer
Monoclonal Gammopathy
Tumors
Image of trial facility.

Cancer Vaccine

for Lung Cancer

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Chemo-Immunotherapy

for Lung Cancer

The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement.. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.
Recruiting1 award Phase 23 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Recruiting1 award Phase 219 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center?
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Lymphoma, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Leukemia and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 316 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Stephen V. Liu, Claudine Isaacs, MD, and Chul Kim.
Where is Lombardi Comprehensive Cancer Center at Georgetown University Medical Center located?
The Lombardi Comprehensive Cancer Center, situated at 3970 Reservoir Road NW, Washington, D.C., is affiliated with MedStar Georgetown University Hospital and focuses on advancing cancer research. It offers a comprehensive range of cancer care services, from screening and prevention to diagnosis, treatment, rehabilitation, and survivorship programs. This center is an integral part of the Georgetown University Medical Center.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center: - **MedStar Health Home Care Patient Financial Services:** Call 301-931-6125 or toll-free at 877-931-3100 ext. 6125. - **Hospital Billing Concerns:** Call 410-933-2424 or toll-free at 800-280-9006. - **Physician Billing Concerns:** Call 703-558-1400 or toll-free at 888-896-1400.
What insurance does Lombardi Comprehensive Cancer Center at Georgetown University Medical Center accept?
The Lombardi Comprehensive Cancer Center, located within MedStar Georgetown University Hospital, accepts most major health insurance plans. Coverage for specific services may vary, so patients are advised to contact their insurance provider to confirm coverage details.
What awards or recognition has Lombardi Comprehensive Cancer Center at Georgetown University Medical Center received?
Lombardi Comprehensive Cancer Center, located at Georgetown University Medical Center in Washington, D.C., is distinguished as the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the area. It serves as the research cornerstone for the MedStar Georgetown Cancer Institute. Additionally, it collaborates with John Theurer Cancer Center at Hackensack University Medical Center in New Jersey as part of an NCI Comprehensive Cancer Center research consortium, emphasizing studies on innovative cancer treatments and technologies to improve patient outcomes.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security